Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...

Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...

Alkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...

Heads of several Global Capability Centres (GCCs) told Reuters they are deploying AI across a host of functions - from marketing and conten...

The shift reflects a structural change in how multinationals use their India operations, moving beyond cost-focused support roles to centre...

Global firms are bringing more work in-house at their India centres. Artificial intelligence is boosting productivity. This reduces relianc...

Novo Nordisk is leveraging Artificial Intelligence to significantly speed up new drug launches. The company expects to cut down the time to...

Dr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...

Corporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...

Eli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The...

Hims stock after Hims & Hers earnings: Hims & Hers Health shares dropped significantly after reporting a surprise first-quarter loss and re...

Last October, Novo Nordisk had shut down its cell therapy unit as part of a broader restructuring, discontinuing development of ⁠the therap...

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...

Novo Nordisk is relaunching a diabetes tablet as Ozempic in the United States. This move aims to boost sales by using the strong brand reco...

Eli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...